Specifically, mycosis fungoides (MF), Sezary syndrome (SS), and primary cutaneous CD30+ lymphoproliferative disorders (LPD) account for 55, 5 and 30% of CTCL, respectively. This evidence concerns the gene TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma.